The Shingrix vaccine, effective against shingles, is now reimbursed at 65% for seniors and particularly for immunocompromised individuals, as announced by Franceinfo. This decision follows a publication in the official journal by the Haute Autorité de Santé. Shingles affects around 300,000 people annually in France, mostly seniors over 60. The vaccine is recommended for those aged 65 and above, as well as immunocompromised individuals from the age of 18, costing approximately 300 euros for two doses.

Source